DRIO: New Client Wins And Pricing Initiatives Will Drive Upside Potential

Key Takeaways

• Shifting focus to high-margin recurring revenue and expanding into digital chronic care markets, with strong early traction in new platform segments.
  
• AI-driven operational efficiencies and signed large health plan deals set the stage for improved profitability and accelerated revenue growth in coming years.
  
• Heavy reliance on large contracts, delayed profitability, increasing competition, and execution risks raise concerns about sustainability and long-term financial stability.

Catalysts

Operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand.

• The company is experiencing a delay in realizing the full impact of recently signed large, multi-condition national health plan deals, with onboarding and revenue generation projected to ramp significantly in late 2025 and into 2026. This anticipated wave of enterprise client go-lives is likely to accelerate recurring revenue growth and improve revenue visibility.
  
• DarioHealth is capitalizing on increased structural demand for digital and integrated chronic disease management platforms, evidenced by a broadened pipeline (now $53M+) and a growing roster of new B2B clients (21 new accounts YTD; targeting 40 for 2025), with 80% of wins involving multi-condition solutions-supporting future user and revenue expansion.
  
• Ongoing integration of AI across operational workflows and care pathways is driving operational efficiencies (targeting 15% YoY OpEx reduction) and improved personalization, which should bolster both net margins and long-term clinical differentiation, positioning the company for scalable earnings growth as automation deepens.
  
• The company is repositioning its business mix towards high-margin, SaaS-like annual recurring revenue through both channel and direct employer partnerships, de-emphasizing one-time payments. This transition is already reflected in B2B2C GAAP gross margin expansion (from 44% to 55% YoY, and ~80% non-GAAP in core channels), supporting gross margin and profitability improvement in future periods.
  
• Expansion of DarioHealth's platform into new high-growth areas like GLP-1 optimization and sleep health in partnership with established channel partners is opening additional, large addressable markets (e.g., $150B sleep market). Early traction suggests potential for significant new client wins and revenue streams, enhancing both top-line potential and multi-condition cross-selling opportunities.

DarioHealth Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming DarioHealth's revenue will grow by 18.3% annually over the next 3 years.
• Analysts are not forecasting that DarioHealth will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate DarioHealth's profit margin will increase from -131.6% to the average US Healthcare Services industry of 8.8% in 3 years.
• If DarioHealth's profit margin were to converge on the industry average, you could expect earnings to reach $3.9 million (and earnings per share of $1.97) by about September 2028, up from $-35.7 million today.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 27.6x on those 2028 earnings, up from -0.6x today. This future PE is lower than the current PE for the US Healthcare Services industry at 54.8x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 11.45%, as per the Simply Wall St company report.

DarioHealth Future Earnings Per Share Growth

Risks

• The company reported a sequential and year-over-year revenue decline, primarily due to the non-renewal of a large national health plan contract and slower-than-anticipated ramp-up from new clients, indicating potential long-term volatility and dependence on large contracts that can materially impact total revenues.
  
• DarioHealth's adjusted estimate for cash flow breakeven has been pushed out by 12 to 15 months (now into late 2026 or early 2027), reflecting challenges in achieving profitability and suggesting a risk of ongoing operating losses that may require additional capital raises, which in turn could dilute existing shareholders and impact future earnings.
  
• The digital health sector remains highly competitive, with recent IPOs (like Hinge Health and Omada) setting industry benchmarks and a need to shift to claims-based billing to access larger profit pools-highlighting execution risk as DarioHealth competes for payer adoption, faces evolving reimbursement models, and must continually adapt to sustain revenue growth and protect margins.
  
• The dependency on converting pipeline opportunities to recurring revenue is critical; any disruptions in client onboarding, delays in signed contracts, or failure to win/retain large enterprise clients, especially as the industry consolidates and moves toward multi-condition value-based platforms, could create sustained shortfalls in revenue and slow ARR expansion.
  
• The company's financial performance is currently reliant on aggressive cost reductions-including workforce integration, offshoring, and AI-enabled efficiencies-to offset sluggish top line growth; if these cost savings are not sufficient or sustainable, or if AI investments do not deliver the expected improvements in operating margins, there is a risk to long-term profitability and net margins.

Valuation

• The analysts have a consensus price target of $39.25 for DarioHealth based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $80.0, and the most bearish reporting a price target of just $12.0.
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $44.9 million, earnings will come to $3.9 million, and it would be trading on a PE ratio of 27.6x, assuming you use a discount rate of 11.4%.
• Given the current share price of $9.41, the analyst price target of $39.25 is 76.0% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.